Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7939372 | 0.98 | TSHR (0.43) | TSHRCES2HSD17B10MGAMGAA | |
| SCHEMBL25802171 | 0.98 | TSHR (0.43) | TSHRCES2HSD17B10MGAMGAA | |
| SCHEMBL26699205 | 0.94 | TSHR (0.46) | TSHRCES2HSD17B10MGAMGAA | |
| SCHEMBL831512 | 0.85 | — | — | |
| SCHEMBL18906900 | 0.81 | TSHR (0.39) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL1038709 | 0.81 | GAA (0.44) | TSHRCES2HSD17B10MGAMGAA | |
| SCHEMBL7051236 | 0.81 | CES2 (0.61) | TSHRCES2FAAHEPHX2CYP2C19 | |
| SCHEMBL18906770 | 0.81 | TSHR (0.39) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL5219102 | 0.80 | ALDH1A1 (0.48) | TSHRCES2MGAMGAASI | |
| SCHEMBL6463788 | 0.79 | TSHR (0.50) | TSHRCES2HSD17B10MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638936-B1 | 3-OXA-8-AZAPROSTAGLANDIN ANALOGS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2011-01-26 | — | — | EP | disclosed |
| US-7205302-B2 | Anticoagulants; antilipemic agents; cardiovascular disorders | NIPPON SHINYAKU CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| CN-1301973-C | Heterocyclic derivatives and medicines | NIPPON SHINYAKU CO LTD (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1400518-B1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | NIPPON SHINYAKU CO LTD (JP) | 2007-01-17 | — | — | EP | disclosed |
| EP-1638936-A1 | 3-OXA-8-AZAPROSTAGLANDIN ANALOGS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | Allergan, Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004108670-A1 | 3-OXA-8-AZAPROSTAGLANDIN ANALOGS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| CN-1516690-A | Heterocyclic derivatives and medicines | �ձ���ҩ��ʽ���� | 2004-07-28 | — | — | CN | disclosed |
| US-20040102436-A1 | Heterocyclic compound derivatives and medicines | NIPPON SHINYAKU CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| US-6734206-B1 | POTENT OCULAR HYPOTENSIVES THAT ARE PARTICULARLY SUITED FOR THE MANAGEMENT OF GLAUCOMA | ALLERGAN, INC. | 2004-05-11 | — | — | US | disclosed |
| EP-1400518-A1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | Nippon Shinyaku Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102436-A1 | Heterocyclic compound derivatives and medicines | CNR2, CNR1, GPR55 | TSHR 427/4885CES2 1123/4885HSD17B10 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.